EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lipoprotein(a) in Cardiovascular Disease: What Clinicians Need to Know: A Narrative Review

Elisabetta Ricottini, Nicolò Graziano Ciavaroli, Anna Di Cristo, Antonio Emanuele Lentini, Teresa Trunfio, Luca D’Antonio, Fabio Mangiacapra, Annunziata Nusca, Valeria Cammalleri, Rosetta Melfi, Nino Cocco, Paolo Gallo und 8 weitere

Therapeutics · 07.04.2026 · 3 (2) · 11

DOI: 10.3390/therapeutics3020011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutics, online erschienen am 07.04.2026. Verfasst von Elisabetta Ricottini und 19 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extensive evidence now confirms Lipoprotein(a) [Lp(a)] as a causal, independent risk factor for atherosclerotic cardiovascular disease. Elevated Lp(a) levels are detected in approximately 20% of the global population, positioning it as a major contributor to residual cardiovascular risk. Circulating Lp(a) levels are determined predominantly by genetic factors, so they are largely unresponsive to lifestyle modifications or conventional lipid-lowering therapies. Therefore, multiple international guidelines now endorse a one-time, lifetime measurement of Lp(a), as lowering Lp(a) concentrations is expected to have a positive impact on the reduction of cardiovascular risk. Currently, the therapeutic landscape of Lp(a) lowering drugs is rapidly evolving. Some RNA-based therapies (antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs)) have been demonstrated to reduce plasma Lp(a) concentrations by up to 98% in early-phase clinical trials. The efficacy and safety of these compounds are currently being evaluated in large-scale cardiovascular outcome trials. The results of these studies will be critical in validating the “Lp(a) hypothesis”: specific reduction of Lp(a) levels can lead to a measurable decrease in cardiovascular events. The purpose of this narrative review is to examine and discuss the available evidence on the role of Lp(a) as a risk factor and pharmacological target to provide a practical tool for decision-making in clinical practice.

Zitieren

APA

Ricottini, E., Ciavaroli, N. G., Cristo, A. D., Lentini, A. E., Trunfio, T., D’Antonio, L., Mangiacapra, F., Nusca, A., Cammalleri, V., Melfi, R., Cocco, N., Gallo, P., Rinaldi, R., Tavernese, A., Piccirillo, F., Gelfusa, M., Antonelli, G., Gatto, L., Muscoli, S., & Ussia, G. P. (2026). Lipoprotein(a) in Cardiovascular Disease: What Clinicians Need to Know: A Narrative Review. Therapeutics, 3(2), 11. https://doi.org/10.3390/therapeutics3020011

Vancouver

Ricottini E, Ciavaroli NG, Cristo AD, Lentini AE, Trunfio T, D’Antonio L, et al. Lipoprotein(a) in Cardiovascular Disease: What Clinicians Need to Know: A Narrative Review. Therapeutics. 2026;3(2):11. doi:10.3390/therapeutics3020011

BibTeX
@article{Ricottini2026,
  author = {Ricottini, Elisabetta and Ciavaroli, Nicolò Graziano and Cristo, Anna Di and Lentini, Antonio Emanuele and Trunfio, Teresa and D’Antonio, Luca and Mangiacapra, Fabio and Nusca, Annunziata and Cammalleri, Valeria and Melfi, Rosetta and Cocco, Nino and Gallo, Paolo and Rinaldi, Raffaele and Tavernese, Annamaria and Piccirillo, Francesco and Gelfusa, Martina and Antonelli, Giorgio and Gatto, Laura and Muscoli, Saverio and Ussia, Gian Paolo},
  title = {Lipoprotein(a) in Cardiovascular Disease: What Clinicians Need to Know: A Narrative Review},
  journal = {Therapeutics},
  year = {2026},
  volume = {3},
  number = {2},
  pages = {11},
  doi = {10.3390/therapeutics3020011}
}
Kostenlos starten →